InsidersTradesSigma
Total declarations
Company
▲ Purchases (20 ops.)
▼ Sales (0 ops.)
Explore the detailed record of transactions filed by FREEMAN KEVIN D, Director. Officer active across 1 companies, notably Galectin Therapeutics INC. Aggregated, 20 filings have been published. Total volume traded: €169k. The latest transaction was filed on 19 May 2022 — Acquisition. Regulator: SEC (Form 4). All data is free.
Declarations20 total
€6,2865,000 shares@ €1.25710.0044% mcap3.7% of flow
Common Stock
SEC:0001133416-22-000063:0·
Ideal exit: 13 Feb 2023 (T+270)
€7,9305,000 shares@ €1.5860.0056% mcap4.7% of flow
Common Stock
SEC:0001133416-22-000057:0·
Ideal exit: 13 Jan 2023 (T+270)
€8,6555,000 shares@ €1.73111.2% of flow
Common Stock
SEC:0001133416-22-000008·
Ideal exit: 16 Oct 2022 (T+270)
€8,6555,000 shares@ €1.73111.2% of flow
Common Stock
SEC:0001133416-22-000010·
Ideal exit: 16 Oct 2022 (T+270)
€8,6555,000 shares@ €1.7310.0061% mcap5.1% of flow
Common Stock
SEC:0001133416-22-000008:0·
Ideal exit: 16 Oct 2022 (T+270)
€8,6555,000 shares@ €1.7310.0061% mcap5.1% of flow
Common Stock
SEC:0001133416-22-000010:0·
Ideal exit: 16 Oct 2022 (T+270)
€10,1235,000 shares@ €2.024613.1% of flow
Common Stock
SEC:0001133416-21-000027·
Ideal exit: 11 Sept 2022 (T+270)
€10,0845,000 shares@ €2.016813.0% of flow
Common Stock
SEC:0001133416-21-000025·
Ideal exit: 2 Sept 2022 (T+270)
€10,1235,000 shares@ €2.02460.0071% mcap6.0% of flow
Common Stock
SEC:0001133416-21-000027:0·
Ideal exit: 11 Sept 2022 (T+270)
€10,0845,000 shares@ €2.01680.0071% mcap6.0% of flow
Common Stock
SEC:0001133416-21-000025:0·
Ideal exit: 2 Sept 2022 (T+270)
€10,3505,000 shares@ €2.069913.4% of flow
Common Stock
SEC:0001133416-21-000023·
Ideal exit: 2 Sept 2022 (T+270)
€10,3505,000 shares@ €2.06990.0072% mcap6.1% of flow
Common Stock
SEC:0001133416-21-000023:0·
Ideal exit: 2 Sept 2022 (T+270)
€5,4262,000 shares@ €2.71327.0% of flow
Common Stock
SEC:0001133416-21-000017·
Ideal exit: 26 Jul 2022 (T+270)
€5,4262,000 shares@ €2.71320.0038% mcap3.2% of flow
Common Stock
SEC:0001133416-21-000017:0·
Ideal exit: 26 Jul 2022 (T+270)
€5,4882,000 shares@ €2.7447.1% of flow
Common Stock
SEC:0001133416-21-000013·
Ideal exit: 18 Jul 2022 (T+270)
€5,4882,000 shares@ €2.7440.0038% mcap3.2% of flow
Common Stock
SEC:0001133416-21-000013:0·
Ideal exit: 18 Jul 2022 (T+270)
€8,6893,000 shares@ €2.896211.2% of flow
Common Stock
SEC:0001133416-21-000011·
Ideal exit: 16 Jul 2022 (T+270)
€8,6893,000 shares@ €2.89620.0061% mcap5.1% of flow
Common Stock
SEC:0001133416-21-000011:0·
Ideal exit: 16 Jul 2022 (T+270)
€9,9073,000 shares@ €3.302312.8% of flow
Common Stock
SEC:0001140361-21-032248·
Ideal exit: 20 Jun 2022 (T+270)
€9,9073,000 shares@ €3.30230.0069% mcap5.9% of flow
Common Stock
SEC:0001140361-21-032248:0·
Ideal exit: 20 Jun 2022 (T+270)
20 of 20 declarations
About FREEMAN KEVIN D
Kevin D. Freeman is an executive at Galectin Therapeutics Inc.
